Revvity Inc.
$ 97.62
0.51%
24 Feb - close price
- Market Cap 11,272,969,000 USD
- Current Price $ 97.62
- High / Low $ 99.37 / 97.28
- Stock P/E 47.15
- Book Value 64.04
- EPS 2.06
- Next Earning Report 2026-04-27
- Dividend Per Share $0.28
- Dividend Yield 0.28 %
- Next Dividend Date 2026-05-08
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 120.05
- 52 Week Low 81.25
About
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$119.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-02 | 2025-10-27 | 2025-07-28 | 2025-04-28 | 2025-01-31 | 2024-11-04 | 2024-07-29 | 2024-04-29 | 2024-02-01 | 2023-10-30 | 2023-08-01 | 2023-05-11 |
| Reported EPS | 1.7 | 1.18 | 1.18 | 1.01 | 1.42 | 1.28 | 1.22 | 0.98 | 1.25 | 1.18 | 1.21 | 1.01 |
| Estimated EPS | 1.58 | 1.14 | 1.14 | 0.95 | 1.38 | 1.13 | 1.12 | 0.94 | 1.16 | 1.19 | 1.19 | 1.02 |
| Surprise | 0.12 | 0.04 | 0.04 | 0.06 | 0.04 | 0.15 | 0.1 | 0.04 | 0.09 | -0.01 | 0.02 | -0.01 |
| Surprise Percentage | 7.5949% | 3.5088% | 3.5088% | 6.3158% | 2.8986% | 13.2743% | 8.9286% | 4.2553% | 7.7586% | -0.8403% | 1.6807% | -0.9804% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-27 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.02 |
| Currency | USD |
Previous Dividend Records
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-02-06 | 2025-11-07 | 2025-08-08 | 2025-05-09 | 2025-02-07 | 2024-11-08 | 2024-08-09 | 2024-05-10 | 2024-02-09 | 2023-11-10 |
| Amount | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 |
Next Dividend Records
| Dividend per share (year): | $0.28 |
| Dividend Yield | 0.28% |
| Next Dividend Date | 2026-05-08 |
| Ex-Dividend Date | 2026-04-17 |
Recent News: RVTY
2026-02-24 07:51:12
Revvity's stock has seen recent weakness, dropping 18% in the past month and 8% in three months. Despite this, the company is considered 15.3% undervalued by its most popular narrative, with a fair value estimated at $114.63, driven by expected margin expansion. However, the article also highlights risks like China reimbursement pressures and a high P/E ratio compared to the industry.
2026-02-24 07:23:17
Revvity (RVTY) has seen an 18% share price decline over the past month, leading to a reassessment of its valuation. Despite the recent weakness and long-term underperformance, the stock is considered 15.3% undervalued by Simply Wall St's narrative, with a fair value of $114.63, driven by an anticipated shift to higher-margin products and cost actions. Investors are encouraged to weigh risks like China reimbursement pressures against potential rewards.
2026-02-24 05:51:08
Shares of Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health all experienced declines following the Trump administration's announcement of new global tariffs, reigniting trade policy uncertainty. The tariffs, imposed using the Trade Act of 1974, created significant concerns for companies reliant on international supply chains. Bio-Techne, specifically, was highlighted for its stock volatility, having previously seen gains after a temporary relaxation of U.S.-China trade tensions.
2026-02-24 03:31:41
Agilent Technologies (NYSE:A) is set to report its Q4 earnings this Wednesday afternoon. The company beat revenue expectations last quarter, reporting $1.86 billion, and analysts anticipate 7.4% year-on-year revenue growth for the upcoming quarter. Despite a market downturn for research tools & consumables stocks, Agilent is heading into earnings with an average analyst price target significantly above its current share price.
2026-02-23 17:32:42
Several stocks, including Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health, experienced declines after the Trump administration announced new global tariffs using the Trade Act of 1974. This move reintroduced trade policy uncertainty in the market, impacting companies reliant on international supply chains. Investors are now assessing the potential effect of these tariffs on corporate earnings and worldwide economic activity.
2026-02-23 17:01:43
Several stocks including Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health experienced declines after the Trump administration announced new global tariffs, citing the Trade Act of 1974. This move reignited trade policy uncertainty, despite an earlier Supreme Court ruling against using a different act for tariffs. Investors are now assessing the potential impact of these duties on corporate earnings and global supply chains.
